<DOC>
	<DOCNO>NCT00601835</DOCNO>
	<brief_summary>To compare seroprotection rate booster responses Canadian-manufactured Tetanus Diphtheria Toxoids Adsorbed vaccine seroprotection rate booster responses US-manufactured Tetanus Diphtheria Toxoids Adsorbed vaccine administer subject ≥ 60 year age . To compare post-vaccination geometric mean titer antibody ( GMTs ) Canadian manufacture Tetanus Diphtheria Toxoids Adsorbed vaccine post-vaccination GMTs US manufacture Tetanus Diphtheria Toxoids Adsorbed vaccine administer subject ≥ 60 year age .</brief_summary>
	<brief_title>Canadian Manufactured Tetanus Diphtheria Toxoids Adsorbed ( Td ) Vaccine Compared With U.S . Manufactured Td</brief_title>
	<detailed_description>This multi-center , partially open-label , partially randomize double blind trial immunogenicity safety United States . Participants enrol one three treatment group : - Subjects age 11-59 year receive Canadian manufacture Td vaccine Day 0 - Subjects 60 year old randomize receive either US manufacture Td Day 0 , , - Subjects 60 year old randomize receive Canadian manufacture Td Day 0 The trial design assess safety Canadian Manufactured Tetanus Diphtheria Toxoids Adsorbed vaccine trial participant 11 59 year age describe immune response subset adolescent ( 11-14 , 15-18 year age ) subset adult 19-59 year age . The trial also compare immune response safety subject ≥ 60 year age receive Canadian Manufactured Tetanus Diphtheria Toxoids Adsorbed vaccine equal number subject ≥ 60 year age receive US Manufactured Tetanus Diphtheria Toxoids Adsorbed vaccine .</detailed_description>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participant healthy per medical history report subject . Participant least 11 year age time vaccination . Participant sign Institutional Review Board ( IRB ) approve informed assent/consent form . For subject 11 17 year age , write informed consent must obtain parent ( ) legal guardian ( ) write informed assent must obtain subject Participant provide history documentation primary booster immunization Diphtheria Tetanus . Female participant childbearing potential must negative urine pregnancy test time enrollment . Serious uncontrolled chronic disease ( i.e. , cardiac , pulmonary , renal , neurologic , metabolic , rheumatologic , etc. ) . Known suspected impairment immunologic function . Acute medical illness without fever within last 72 hour oral temperature ≥ 100.4°F ( ≥ 38°C ) time enrollment . Administration immune globulin blood product within last three month ; administration corticosteroid ( injected oral ) immunomodulatory therapy within six week study vaccine . However , individual taper dose schedule oral steroid may include trial , long steroid discontinue two week prior enrollment . Received vaccine , influenza vaccine , 28day period prior enrollment schedule receive vaccination , influenza prior Visit 2 blood draw . For influenza vaccine , exclude received 14 day period prior enrollment schedule receive 14 day period Visit 1 . Suspected known hypersensitivity Td component , thimerosal ( subject &gt; 60 year age ) latex rubber . Unable attend schedule visit unable comply study procedure . Enrolled another clinical trial . Any condition would pose health risk participant interfere evaluation vaccine opinion investigator . A positive urine pregnancy test time enrollment female childbearing potential . Female childbearing potential agree either remain abstinent use effective birth control period trial . Breast feeding period trial . A history Guillain Barré syndrome within 6 week previous dose tetanus toxoidcontaining vaccine . Receipt tetanus diphtheria vaccination within 5 year prior enrollment . A previous history diphtheria disease within last 25 year tetanus disease History Arthustype hypersensitivity reaction temperature &gt; 103° F follow prior dose tetanus toxoid , unless 10 year elapse since previous dose .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
</DOC>